IKCS 2022
IKCS 2022
Advertisement
Robert DillardIKCS 2022 | March 11, 2024
A study evaluated how accurately prospectively collected renal mass biopsy can identify DNA mutations in nephrectomy.
Read More
Robert DillardIKCS 2022 | February 1, 2023
Gut bacteria play a role in the development of sarcopenia in metastatic renal cell carcinoma.
Robert DillardIKCS 2022 | February 1, 2023
Following AUA guidelines may increase survival in kidney cancer.
Robert DillardIKCS 2022 | February 1, 2023
An algorithm for assessing solid renal masses called the kidney MR score proved successful in differentiating lesions.
Robert DillardIKCS 2022 | January 17, 2023
Active surveillance appears effective in renal transplant candidates and immunocompromised patients with small renal mass.
Robert DillardIKCS 2022 | February 1, 2023
Immune-oncology agents and tyrosine kinase inhibitors are increasingly being used in treating metastatic kidney cancer.
Robert DillardIKCS 2022 | March 10, 2023
Patients presenting with nasal or paranasal sinuses tumors should be checked for metastatic kidney cancer.
Robert DillardIKCS 2022 | March 10, 2023
Patients with kidney cancer who exercise and stay physically active have better physical and mental health.
Robert DillardIKCS 2022 | February 1, 2023
Artificial intelligence models can accurately predict cardiotoxicity risk in patients with renal cell carcinoma.
Robert DillardIKCS 2022 | March 10, 2023
Patients who undergo treatment for renal cell carcinoma (RCC) have a 10-times greater risk of end-stage renal disease (ESRD).
Robert DillardIKCS 2022 | February 1, 2023
Cabozantinib and avelumab appears safe and effective in patients with metastatic clear cell renal carcinoma.
Robert DillardIKCS 2022 | March 10, 2023
Patients with advanced renal cell carcinoma demonstrate better responses on nivolumab plus cabozantinib.
Advertisement
Advertisement
Advertisement